December 7, 2022
Alessandro Fatatis is appointed Associate Director for Basic Research at the Sidney Kimmel cancer Center of Thomas Jefferson University.
August 18, 2022
This new grant will support studies employing animal models of metastasis, human cell lines, PDX-derived cells and human tissue samples to ascertain the functional role of IL-1𝛽 in skeletal colonization of prostate cancer cells, discriminating between direct autocrine-paracrine effects on cancer cells and targeting cells of the tumor-associated bone stroma. Furthermore, we will identify the bone stroma cells targeted by IL-1𝛽 and evaluate three stromal factors secreted in response to IL-1𝛽 for the ability to induce AR signaling and expression of AR-regulated genes. Finally, using a combination of molecular biology approaches we will define the mechanism for the transcriptional regulation of IL-1𝛽 by the AR and validate this mechanism in animal models of disease.
This new grant will support collaborative studies between our group and the lab of Dr. David Sykes at the Harvard Stem Cell Institute. The research project titled Direct and combinatorial anti-tumor effects of CX3CR1 antagonists in prostate cancer, will be funded for one year.
Anna Zhang passes her Qualifying Exam and is now a PhD candidate
Anthony DiNatale starts as a post-doctoral fellow at Janssen in
the Exploratory Biology/Therapeutic Discovery Group
Our work was selected for presentation in the minisymposium on Molecular Principles of Metastasis at the AACR annual meting in New Orleans and Anna presented the talk:
Subsets of cancer cells expressing CX3CR1 are endowed with tumor-initiating properties and resistance to chemotherapy
Anthony DiNatale successfully defending his thesis titled ” Newly identified mediators and mechanisms promoting metastatic prostate cancer” on April 9th, 2021.
